What the evidence shows — and what it cannot yet confirm

How well does ChondroFiller gel hold up over time? That is the practical question most patients bring to a consultation, and the published data offer a reasonably clear — if still incomplete — answer.

Across knee and hip cohorts, clinical series consistently report statistically significant improvements in validated functional scores, including the IKDC and Lysholm scales, sustained through 12 months of follow-up. The most extensive dataset comes from a prospective hip cohort (n=26, acetabular lesions greater than 2 cm²) in which 17 of 21 evaluable patients — 81% — achieved good-to-excellent results at serial assessments spanning 3 to 5 years post-treatment, making it the only published ChondroFiller series to reach and surpass the 36-month window with MRI-confirmed cartilage healing.

What the evidence cannot yet confirm is equally important to state plainly. No adequately powered randomised controlled trial has completed follow-up at 24 or 36 months, which means head-to-head durability comparisons with microfracture or other cartilage repair approaches remain inconclusive at those time points. The body of evidence is best understood as promising and clinically consistent, but not yet the scale of data behind established long-term interventions. Patient selection and lesion characteristics also appear to influence outcomes significantly, as discussed in the sections that follow.

Knee outcomes: functional gains and a mid-year plateau

The knee-specific data come from two complementary sources separated by nearly a decade. In a 2016 prospective multicenter trial — the first formally randomised study of the scaffold — 13 patients receiving ChondroFiller showed statistically significant improvements in IKDC scores at 3, 6, and 12 months compared with pre-operative baseline (p<0.05), with no adverse events recorded across the study period. Alongside the functional scores, MRI MOCART assessments at 4 weeks and 52 weeks documented immediate defect filling at the earliest imaging point, followed by progressive cartilage maturation through to 12 months, with published reports describing integration with adjacent cartilage visible from the outset.

A 2024 knee series of 17 patients (mean age 31 years, followed to 12 months) corroborates this functional trajectory using both Lysholm and IKDC scores, again recording statistically significant gains at 3, 6, and 12 months. The series adds a clinically relevant nuance: the difference between 6-month and 12-month scores was not statistically significant, pointing to a functional plateau in the second half of the first year. In plain terms, the measurable gains appear to accumulate relatively quickly — largely within the first six months — and then stabilise rather than continuing to accumulate. For clinical practice, this pattern may influence how early a meaningful responder assessment can reasonably be made and when a structured follow-up review is most informative.

Hip and small joint data: how far the evidence extends

Beyond the knee, two datasets extend both the joint range and the follow-up horizon of ChondroFiller evidence.

The longer-term picture comes from a 2021 prospective hip cohort of 26 patients with acetabular cartilage lesions exceeding 2 cm². In that series — the only published ChondroFiller dataset to cross the 36-month threshold — serial assessments at three, four, and five years showed 17 of 21 evaluable patients (81%) maintaining good-to-excellent outcomes, supported by MRI-confirmed cartilage healing that was statistically significant against pre-operative status. Five-year follow-up matters in cartilage repair because regenerated tissue must withstand sustained mechanical loading; data at this interval give a more reliable indication of biological durability than shorter-term functional scores alone. Patient selection proved consequential: pre-existing osteoarthritis at Tönnis grade 2–3 was consistently associated with poorer results, identifying it as a meaningful contraindication rather than a minor caveat. Placement in this study cohort was performed arthroscopically, which was the research method used; current outpatient treatment pathways operate on a different delivery basis.

A 2025 wrist study — 25 patients treated with ChondroFiller compared with 7 matched controls, assessed at follow-up arthroscopy — found markedly better cartilage quality in the treated group: median Outerbridge score 1.5 versus 3.0 (p=0.006) and ICRS grade 1 versus 3 (p=0.002). This extends the biological signal to small joints, though the control group is modest in size, and joint-specific factors will affect how directly these findings transfer across anatomical sites.

Why the scaffold is designed for gradual recovery

The recovery logic behind ChondroFiller rests on two distinct biological phases, and laboratory evidence for both has now been published.

The first phase is cell recruitment. Rather than delivering repair cells pre-loaded into the scaffold, ChondroFiller works by drawing the body's own stem cells into its collagen matrix once it is in place. A 2025 ex vivo study using human osteochondral tissue measured a 2.4-fold increase in DNA content within ChondroFiller-treated samples by day 14 — a direct count of cellular activity that quantifies how effectively the scaffold attracts resident repair cells in the early weeks after treatment.

The second phase is mechanical integration, and here a 2024 in-vitro study offers an important counterpoint. Under repeated joint-load conditions — a laboratory simulation of normal walking forces applied in controlled cycles — ChondroFiller-filled defects performed no better than unfilled defects at protecting the opposing cartilage surface. The authors attribute this to the gel's mechanical fragility before it has had time to consolidate in the joint. This is not a defect in the material; it is a property of its early state, and it provides a clear scientific basis for the clinical recommendation to defer full weight-bearing until consolidation is established.

Taken together, the two findings map directly onto the functional picture the clinical data describe: an active period of biological repair in the early months, followed by gradual load-bearing capacity as the maturing scaffold integrates structurally — a sequence consistent with functional gains that appear to peak within the first year.

Who responds well — and where the evidence falls short

The patient profile that fits most cleanly within the published evidence is a younger adult — the 2024 Bulgarian knee series enrolled patients with a mean age of 31 — with a focal cartilage lesion on an otherwise structurally sound joint. As already noted from the hip cohort, moderate-to-severe pre-existing osteoarthritis marks the boundary of the evidence rather than its centre, and patient selection on that basis is the single most consistent clinical moderator across studies.

On technique, one avoidable safety signal stands out. In the 2025 wrist series, fibrous tissue formation occurred only in defects that were overfilled; applications placed flush with the surrounding cartilage surface were complication-free. This is less a warning about the material than a reminder that accurate, image-guided placement is a critical part of the treatment — not an incidental detail.

The most significant limitations lie in study scale and design. Across the strongest published datasets, the number of patients receiving ChondroFiller ranges from 8 to 26. The only nominally randomised knee trial could not sustain its comparison arm: six of ten patients allocated to microfracture declined the procedure, which means results at 12 months are descriptive rather than genuinely comparative. Beyond that point, no trial has produced a valid control arm at 24 or 36 months. The specific unanswered questions are therefore: how does durability compare with microfracture, autologous cell implantation, or other scaffolds over two to three years, and do the 12-month functional gains hold across a broader age and defect-size range? Larger prospective studies are needed to address both.

What this evidence means for a treatment decision

The picture that emerges has a practical shape. ChondroFiller occupies a specific, evidence-bounded position: a regenerative collagen scaffold for focal cartilage lesions on joints without significant background osteoarthritis — not a symptom manager for generalised wear. That distinction determines who is likely to benefit and who falls outside the evidence base.

For a suitable candidate, the data support a reasonable expectation of meaningful functional gain within 12 months. The plateau pattern identified in the knee series has a clinical upside: because gains tend to stabilise within the first year, a structured review at or before 12 months gives both patient and clinician enough information to judge whether treatment has delivered — without waiting years for a verdict.

What the evidence does not yet permit is a confident comparison with microfracture, autologous cell implantation, or other scaffolds beyond 12 months. Patients weighing alternatives should know that gap remains open, and that the current trial base — though clinically consistent — has not yet settled the question at scale.

The appropriate next step for anyone at the decision stage is a structured suitability assessment — covering defect size, OA grade, joint loading, and functional goals — rather than a treatment commitment. An eligibility assessment is available at amsk.co.uk for patients wanting to establish whether their situation fits the evidence profile described here.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
3. [3] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid (cell free 2-component collagen gel) with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759